NEW ORLEANS–(BUSINESS WIRE)–Former Louisiana Attorney General Charles C. Foti, Jr., Esq., partner at the law firm Kahn Swick & Foti, LLC (“KSF”), announces that KSF has opened an investigation into Spectrum Pharmaceuticals , Inc. (NasdaqGS: SPPI).
On August 6, 2021, the Company announced the receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the application for its drug candidate, ROLONTIS, which highlighted manufacturing defects and indicated that a re-inspection of the Company’s manufacturing facility would be required.
Subsequently, the Company and certain of its officers were sued in a securities class action lawsuit, accusing them of failing to disclose material information during the Class Period in violation of federal securities laws. securities, which are still ongoing.
KSF’s investigation focuses on whether Spectrum’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that could help KSF in its investigation, or if you have been a long-term holder of Spectrum stock and wish to discuss your legal rights, you may, at no obligation or cost to you, call toll-free at 1-877-515-1850 or email Lewis Kahn, KSF Managing Partner (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-sppi/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s leading securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, fund managers and retail investors – in seeking recoveries for investment losses resulting from corporate fraud or malfeasance by listed companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you can visit www.ksfcounsel.com.
